ABA. G. Christina Bergqvist

A. G. Christina Bergqvist

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


A. G. Christina Bergqvist has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Virginia A. Stallings

    Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Department of Pediatrics and Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.

    3 shared publications
  • Claire M. Chee

    Divisions of Neurology, Cardiology, Gastroenterology and Nutrition, and the Department of Nutrition Services, The Children's Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.

    2 shared publications
  • Joan I Schall

    From the Divisions of Neurology (AGCB), and Gastroenterology, Hepatology, and Nutrition (JIS, VAS, and BSZ), The Children's Hospital of Philadelphia, Department of Pediatrics and Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA

    2 shared publications
  • Joan I. Schall

    Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Department of Pediatrics and Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.

    2 shared publications
  • Virginia A Stallings

    From the Divisions of Neurology (AGCB), and Gastroenterology, Hepatology, and Nutrition (JIS, VAS, and BSZ), The Children's Hospital of Philadelphia, Department of Pediatrics and Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA

    2 shared publications
  • Amy R. Brooks-Kayal

    Pediatric Regional Epilepsy Program, Division of Neurology, The Children's Hospital of Philadelphia

    1 shared publication

Latest Publications

  • Early EEG improvement after ketogenic diet initiation

    by Sudha Kilaru Kessler, Paul R. Gallagher, Renée A. Shellhaas, Robert R. Clancy, A.G. Christina Bergqvist


  • Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet

    by Ag Christina Bergqvist, Joan I Schall, Virginia A Stallings, Babette S Zemel

    Background: The ketogenic diet (KD) is a high-fat, low-carbohydrate, and protein diet that effectively treats intractable epilepsy (IE). Objective: The purpose of this study was to measure the change in bone mineral content (BMC) in children with IE treated with the KD for 15 mo. Design: Prepubertal children ≥5 y of age with IE were eligible. A 4:1 ketogenic diet was maintained for 15 mo, and whole-body and spine BMCs were measured with dual-energy X-ray absorptiometry. Z scores were generated by comparing the children with IE with a cohort of 847 healthy children. Other measurements included demographics, anthropometry, serum 25-hydroxyvitamin D (25-OHD), intact parathyroid hormone, electrolytes, and dietary intake. All measurements were performed at baseline and at 3, 6, 12, and 15 mo. Longitudinal mixed effects models were used to analyze change in BMC over time. Results: Twenty-five children (9 girls, 16 boys) with IE [age (x̄ ± SD): 7.3 ± 1.9 y] participated. Growth and bone health status were suboptimal as were serum 25-OHD concentrations and dietary intake of calcium and vitamin D. Whole-body and spine BMC-for-age both declined by 0.6 z score/y and whole-body and spine BMC-for-height declined 0.7 z score/y and 0.4 z score/y, respectively. Height declined 0.5 z score/y. Body mass index (BMI; in kg/m2) z score, age, and ambulation were positive predictors of BMC, which declined sharply over 15 mo of KD treatment. Conclusion: Bone health in children with IE was poor, particularly for younger nonambulatory children with low BMI status. The KD resulted in progressive loss of BMC. The mechanism is unclear. Further studies are needed.


  • Growth failure in children with intractable epilepsy is not due to increased resting energy expenditure

    by A G Christina Bergqvist, Jillian Trabulsi, Joan I Schall, Virginia A Stallings

    The aim of this study was to evaluate the resting energy expenditure (REE) of children with intractable epilepsy (IE) compared with healthy children, and to determine factors that contribute to the pattern of REE. REE, growth status, and body composition were assessed in 25 prepubertal children with IE (15 males, 10 females; mean age 5y 5mo [SD 2y 2mo] range 2–9y) with and without cerebral palsy (CP) and compared with those in 75 healthy children of similar age, sex, and fat free mass (FFM; 43 males, 32 females; mean age 6y 4mo [SD 1y 8mo], range 2–9y). Of the 25 children with IE, 12 had generalized and 13 partial seizures; 10 children had CP (four hemiplegia, one diplegia, and five tetraplegia); 18 were ambulators. REE (kcal/d), determined by indirect calorimetry, was expressed as a percentage of that predicted using Schofield equations. Energy intake from 3‐day weighed food records was assessed for children with IE only and expressed as a percentage of estimated energy requirement. Compared with healthy children, children with IE had significantly lower percentage (Student's t‐test, pp=0.016). In children with IE, energy intake was also a statistically significant predictor of REE. CP largely explained the suboptimal growth status and lower REE of children with IE compared with healthy children.


  • Predictive Power of First Morning Glucose and the Ketogenic Diet

    by A. G. C. Bergqvist, J. I. Schall, E. L. Richard, P. R. Gallagher, V. A. Stallings

    The purpose of this study was to determine if hypoglycemia or hyperglycemia predicts the response to a ketogenic diet (KD) in a cohort of children with intractable epilepsy. We evaluated whether morning blood glucose during the initial 21 days after initiation of the KD in children with IE was related to seizure reduction after 3 months of treatment. The relation between change in weight status and blood glucose was also explored. Fasting morning whole blood glucose was measured each day for the first 21 days after initiation of KD. Weight and height were obtained at baseline, day of discharge, and at 0.5 and 1 month of full KD therapy. Associations among clinical response to the KD (responder status defined as >50% reduction of seizure frequency at 3 months), hypoglycemia, hyperglycemia, style of KD initiation protocol (fasting or gradual) and weight status were evaluated. Forty-five subjects age 1-12 years were enrolled. KD responder status was not associated with low or elevated blood glucose or type of initiation style protocol. Variability in day-to-day blood glucose also did not predict response to KD. Children who had declining weight status during KD initiation were more likely to be hypoglycemic during full KD therapy. Low blood glucose during KD therapy was not necessary for clinically significant seizure reduction. Hypoglycemia was related to declining weight status irrespective of initiation style protocol. An effective KD can be provided in a manner to minimize side-effects and maximize efficacy.


  • Vitamin D Status in Children with Intractable Epilepsy, and Impact of the Ketogenic Diet

    by A.G. Christina Bergqvist, Joan I. Schall, Virginia A. Stallings

    Summary:  Purpose: The aim of this study was to describe vitamin D status in children with intractable epilepsy prescribed newer antiepileptic drugs (AEDs) before initiation of and during 15‐month treatment with the ketogenic diet (KD). Methods: Serum vitamin D (25‐OHD and 1,25‐OHD) and parathyroid hormone (PTH) were assessed in prepubertal children with intractable epilepsy before initiation of and during KD therapy. Three‐day weighed dietary records including KD and vitamin and mineral supplementation were obtained at baseline and at 1 month. Results: Forty‐five children (aged 5.1 ± 2.7 years) were enrolled. Before KD therapy, 4% had deficient and 51% had insufficient serum 25‐OHD levels. Vitamin D intake was less than recommended in 47%. Adequate vitamin D intake, fewer AEDs, and generalized seizures were associated with higher serum 25‐OHD levels (p < 0.01). After 3 months on the KD, 25‐OHD levels increased (p < 0.001), and PTH declined (p < 0.001). Over the next 12‐month period, 25‐OHD levels steadily declined (p < 0.001), and PTH did not significantly change. Conclusions: Children with intractable epilepsy treated with newer AEDs had poor vitamin D status. Their status improved over the first 3 months of KD therapy with vitamin D supplementation and slowly declined thereafter.


  • Fasting versus Gradual Initiation of the Ketogenic Diet: A Prospective, Randomized Clinical Trial of Efficacy

    by A. G. Christina Bergqvist, Joan I. Schall, Paul R. Gallagher, Avital Cnaan, Virginia A. Stallings

    Summary: Purpose:The ketogenic diet (KD) is a 90% fat diet that is an effective treatment for intractable epilepsy. Rapid initiation of the KD requires hospital admission because of the complexity of the protocol and frequent mild and moderate adverse events. The purpose of the study was to compare the efficacy of a gradual KD initiation with the standard KD initiation preceded by a 24‐ to 48‐h fast.Methods:Children ages 1 to 14 years with intractable epilepsy were randomized to a fasting initiation (FAST‐KD) or gradual initiation (GRAD‐KD). Baseline seizure activity was recorded daily for 28 days before admission and continued for the 3‐month duration of the study. Effectiveness was measured in two ways: (a) the proportion of subjects with >50% reduction in target seizure type from baseline to 3‐month evaluation, and (b) percentage reduction in the frequency of the target seizure type from baseline to 3‐month evaluation. Blood glucose was assessed q4 to 6h, and weights, electrolytes, hydration status, vomiting, acid balance, need for interventions (citric acid and sodium citrates (Bicitra) and IV fluids) were assessed daily. Fisher's exact tests were used to examine the association between protocol and occurrence of adverse events, and longitudinal mixed‐effects models were used to look for trends in tolerability data over time.Results:Forty‐eight subjects, 24 in each arm, were randomized. In the FAST‐KD protocol, 58% of the children had >50% reduction in the target seizure type at 3 months, and 21% were seizure free. In the GRAD‐KD protocol, 67% had a >50% reduction at 3 months, and 21% were seizure free. The two protocols were equivalent in efficacy (p = 0.033). At 3 months, the FAST‐KD median percentage seizure reduction rate was 78% (ranging from 100% reduction to 73% increase in seizures per week) and was 94% (ranging from 100% reduction to 161% increase in seizures per week) for the GRAD‐KD protocol. By using a logarithmic transformed percentage reduction rate and an equivalence limit difference of 20%, the efficacy of the two protocols was equivalent (p = 0.0002). Children in the GRAD protocol lost significantly less weight (p = 0.006), and had fewer and less‐severe episodes of hypoglycemia (p < 0.001), fewer treatments for acidosis (citric acid and sodium citrates) (p < 0.04) and dehydration (IV fluids) (p < 0.04), but no difference in vomiting was noted.Conclusions:These data suggest that in children with intractable epilepsy, a gradual initiation results in fewer adverse events and is tolerated better overall while maintaining the efficacy of the KD.


  • Open Access

    Selenium Deficiency Associated with Cardiomyopathy: A Complication of the Ketogenic Diet

    by A. G. Christina Bergqvist, Claire M. Chee, Lisa Lutchka, Jack Rychik, Virginia A. Stallings

    Summary:  Purpose: The ketogenic diet (KD) is an efficacious treatment for intractable epilepsy, associated with infrequent side effects. The KD is known to be deficient in most vitamins and minerals and may be deficient in trace minerals. We report biochemical selenium deficiency in nine patients on the KD, including one who developed cardiomyopathy.Methods: A whole‐blood selenium level was obtained on the symptomatic patient after noting the patient's poor appearance on physical examination. Children already treated and children beginning the KD were then evaluated prospectively for selenium status by measuring whole‐blood or serum selenium as part of routine laboratory evaluation every 3 months.Results: The index case had no detectable whole‐blood selenium. Cardiac physical examination and ECG were normal, but the echocardiogram revealed cardiomyopathy. Thirty‐nine additional children had the selenium status evaluated. Eight had selenium levels below the normal range (six initially, and two developed low selenium levels on serial testing). They were referred for cardiology evaluations, which were normal. Selenium supplementation improved levels in all children. Low levels were seen in some children after only a few months of treatment.Conclusions: The nutrient adequacy of the currently used KD has not been fully evaluated. The nutrient content of KD with usual supplements may not meet Recommended Dietary Allowances (RDA) for selenium and may not provide other trace minerals in adequate amounts. At our center, selenium deficiency was found in 20% of the patients evaluated. Screening for selenium deficiency is suggested if the patient KD regimen does not meet ≥75% of the RDA or if the child is symptomatic. Nutrient supplementation should provide adequate trace elements for children treated with the KD. The KD requires close monitoring of the overall nutritional status.